198 related articles for article (PubMed ID: 34669981)
21. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine, Campath, and Low-Dose Cyclophosphamide (FCC
Shah RM; Truong TH; Leaker MT; Wright NAM; Le D; Steele M; Bruce AAK; Desai S; Guilcher GMT; Lewis V
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1900-1905. PubMed ID: 32640311
[TBL] [Abstract][Full Text] [Related]
23. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
Eapen M; Brazauskas R; Williams DA; Walters MC; St Martin A; Jacobs BL; Antin JH; Bona K; Chaudhury S; Coleman-Cowger VH; DiFronzo NL; Esrick EB; Field JJ; Fitzhugh CD; Kanter J; Kapoor N; Kohn DB; Krishnamurti L; London WB; Pulsipher MA; Talib S; Thompson AA; Waller EK; Wun T; Horowitz MM
J Clin Oncol; 2023 Apr; 41(12):2227-2237. PubMed ID: 36623245
[TBL] [Abstract][Full Text] [Related]
24. Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial.
Ozdogu H; Boga C; Yeral M; Kozanoglu I; Gereklioglu C; Aytan P; Kasar M; Asma S; Buyukkurt N; Solmaz S; Korur A; Sariturk C
Bone Marrow Transplant; 2018 Jul; 53(7):880-890. PubMed ID: 29403023
[TBL] [Abstract][Full Text] [Related]
25. The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study.
Nickel RS; Flegel WA; Adams SD; Hendrickson JE; Liang H; Tisdale JF; Hsieh MM
EClinicalMedicine; 2020 Jul; 24():100432. PubMed ID: 32637902
[TBL] [Abstract][Full Text] [Related]
26. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.
Childs R; Clave E; Contentin N; Jayasekera D; Hensel N; Leitman S; Read EJ; Carter C; Bahceci E; Young NS; Barrett AJ
Blood; 1999 Nov; 94(9):3234-41. PubMed ID: 10556212
[TBL] [Abstract][Full Text] [Related]
27. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
van Besien K; Dew A; Lin S; Joseph L; Godley LA; Larson RA; Odenike T; Rich E; Stock W; Wickrema A; Artz AS
Leuk Lymphoma; 2009 Nov; 50(11):1809-17. PubMed ID: 19821799
[TBL] [Abstract][Full Text] [Related]
28. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
30. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
[TBL] [Abstract][Full Text] [Related]
31. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V
Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838
[TBL] [Abstract][Full Text] [Related]
32. Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant.
Chan WYK; Kwok JSY; Chiang AKS; Chan GCF; Lee PPW; Ha SY; Cheuk DKL
Pediatr Transplant; 2021 Aug; 25(5):e13945. PubMed ID: 33314508
[TBL] [Abstract][Full Text] [Related]
33. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.
Gandhi S; Kulasekararaj AG; Mufti GJ; Marsh JC
Int J Hematol; 2013 May; 97(5):573-80. PubMed ID: 23632948
[TBL] [Abstract][Full Text] [Related]
35. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
Haines HL; Bleesing JJ; Davies SM; Hornung L; Jordan MB; Marsh RA; Filipovich AH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):288-92. PubMed ID: 25464116
[TBL] [Abstract][Full Text] [Related]
37. Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.
Kreiter S; Winkelmann N; Schneider PM; Schuler M; Fischer T; Ullmann AJ; Huber C; Derigs HG; Kolbe K
Bone Marrow Transplant; 2001 Jul; 28(2):157-61. PubMed ID: 11509933
[TBL] [Abstract][Full Text] [Related]
38. Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study.
Achini-Gutzwiller FR; Schilham MW; von Asmuth EGJ; Jansen-Hoogendijk AM; Jol-van der Zijde CM; van Tol MJD; Bredius RGM; Güngör T; Lankester AC; Moes DJAR
Blood Adv; 2023 Aug; 7(16):4462-4474. PubMed ID: 37285798
[TBL] [Abstract][Full Text] [Related]
39. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.
Willemsen L; Jol-van der Zijde CM; Admiraal R; Putter H; Jansen-Hoogendijk AM; Ostaijen-Ten Dam MM; Wijnen JT; van Kesteren C; Waaijer JL; Lankester AC; Bredius RG; van Tol MJ
Biol Blood Marrow Transplant; 2015 Mar; 21(3):473-82. PubMed ID: 25485863
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow transplant using fludarabine-based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia.
Gorfinkel L; Demsky C; Pashankar F; Kupfer G; Shah NC
Pediatr Transplant; 2021 Jun; 25(4):e14009. PubMed ID: 33755277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
